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Abstract
The blood protein vitronectin has been found to perfonn a variety of functions in the
human body. Among these is its role in blood clot fonnation, the immune system, and
tissue remodeling. By binding to the urokinase plasminogen activator receptor (uP AR),
vitronectin facilitates cell adhesion and regulates tissue remodeling. This is a process that
takes place in the fonnation of tumors and the progression of cancer cells. Vitronectin
has also been found to playa key role in such pathogenic processes as invasion by

Candida albicans yeast, which cause infections in immunocompromised hosts. This
project aims to develop a better understanding of the molecular and cellular interactions
of vitronectin binding to ligands. It aims to test the binding of vitronectin to the
urokinase receptor and the effects of various factors on this binding. Among these
factors are the interaction of vitronectin with Plasminogen Activator Inhibitor-l (PAl -1)
and the Extracellular Matrix (ECM) and the fonnation of multimeric vitronectin
complexes. To detennine the effects of these factors on vitronectin-urokinase receptor
interaction, studies were conducted in vitro using isolated uP AR. These studies were
perfonned by using the enzyme linked immuno-sorbent assays (ELISA) methods. The
results of these experiments show a competition of PAI-l with the urokinase receptor for
binding to vitronectin. While these results agree with recent structural studies of the
receptors that have been pursued, they contrast with previous observations of the effects
of PAI-l on the binding ofvitronectin to another class of receptors, integrins. ELISA
methods were also employed to develop appropriate conditions for the study of the
binding of vitronectin to C. albicans cells. These assays showed increased binding to
ECM with increased concentration. The aspects that were evaluated included

determination appropriate cell growth conditions, assay blocking agents, and cell growth
media. The ability to measure the competitive and additive effects of ligand interactions
on vitronectin can lead to a better understanding of such physiological processes as
coagulation and angiogenesis, as well as lead to the development of therapeutic agents for
certain diseases.

Introduction

Vitronectin is a plasma glycoprotein that has been found to participate in a variety of functions in
the human body. As it is present both in circulation and in the extra cellular matrices of cells,
vitronectin plays an important role is such processes as coagulation and cell adhesion. It thus
leads to many effects dealing with the immune system, tissue remodeling, and angiogensis.
Many of the functions ofvitronectin are mediated by interactions with other proteins in the body.
These include binding to cell-surface receptors such as integrins and the urokinase-type
plasminogen activator receptor (uPAR). This binding interaction, which affects cell properties
and functions, is affected by vitronectin binding to substrates like the type I plasminogen
activator inhibitor (PAl-I).

Vitronectin is an adhesive protein that is found in human plasma, in circulation and in
associations with matrices of connective tissues and fibers. It is produced mainly by the liver,
but other tissues such as platelets and macrophages contain an immunochemically identical
protein (Preissner and Jenne (2)). Vitronectin has been found to exist in three main forms. Full
length vitronectin exits as a folded monomer in plasma, whereas it exists as a multimer in
associations with ECM and other ligands. Also, vitronectin has been identified in a two-chain
form in the blood, where cleavage of vitronectin by an unkown protease results in two chains
joined by a disulfide bond; this has shown very little difference in function from full length
vitronectin (Schroeck, et al.) While the detailed overall structure ofvitronectin has not yet been
fully elucidated, general features of the structure have been determined. The molecular structure
was determined by sequencing of human and rabbit vitronectin cDNA and by analysis of exonintron organization ofthe human gene. Amino acid residues 3-42 of the amino terminal of the

polypeptide chain are termed the "somatomedin B" domain. This domain contains eight
interlinked cysteines and exhibits an overall acidic character. In the amino terminal region of the
protein, four functionally important features are found. These include an arginine-glycineaspartate (RGD) sequence that mediates binding ofvitronectin to certain integrin receptors, a
highly acidic region, putative crosslinking sites, and a binding site for the ECM component
collagen. With its various binding domains, that include ones for associations with the
glycosaminoglycan heparin and thrombin, vitronectin also has the ability to maintain different
conformations. These properties allow vitronectin to be involved as an adhesive component and
function in multiple haemostatic processes that include coagulation, fibrinolysis, and the
plasminogen activation system (Preissner and Jenne (1)).

Vitronectin plays an important role in thrombosis and haemostasis through its associations with
serine proteinase inhibitors (serpins) like anti-thrombin and plasminogen activator inhibitor type
1 (PAl -1). This association affects binding of vitronectin in the extracellular matrix to cell
surface receptors like the urokinase plasminogen activator receptor, thus affecting cell adhesion,
attachment and spreading, and migration. PAI-l plays a key regulatory function in proteolytic
processes that affect both tissue remodeling and tumor metastasis (Minor and Peterson). These
effects of PAI-l are mediated by its complex-formation with vitronectin and by its role in being
the main inhibitor of both plasminogen activators, the urokinase type and the tissue type. A
unique feature of this protein among serpins is its ability to persist in an active form that makes
its reactive center loop accessible as well as a more stable inactive latent conformation that
inserts the reactive center loop into the middle of the structure. When PAI-l is bound to
vitronectin, it remains in its active form for an extended period of time and its half-life is

significantly increased. This binding changes the conformation of vitronectin, leading to
mulitmerization, affecting its functions in the body. The main PAI-l binding region of
vitronectin has been shown to be localized within the amino terminal somatomedin B (SMB)
domain; another lower affinity binding site in the carboxy terminal region has been implied and
seems to be involved in the formation oflarger complexes (Schroeck, et al.). Formation of these
complexes directly affects the binding of cells to the extracellular matrix through such cell
surface receptors as the urokinase plasminogen activator receptor.

The plasminogen system has been found to play an important role in the remodelling of the
extracellular matrix, cellular adhesion and migration; it is thus involved in inflammation, wound
repair, angiogenesis, and tumor development. These effects take place by the generation of
pericellular plasmin by urokinase plasminogen activator (uP A) followed by direct or indirect
proteolysis ofthe extracellular matrix. uP A proteolytically activates plasmin by cleaving its
zymogen, plasmonigen. The urokinase receptor (uP AR), which is a glycosylphosphatidylinositol
(GPI) glycolipid-anchored receptor, binds urokinase and coordinates and focuses this plasminmediated cell-surface proteolysis. uP AR interacts with uP A in both its two-chain active form
and its inactive single chain pro-enzyme form (pro-uP A) (Waltz, et al.). Although the
uP ARluP A complex is relatively stable on the cell-surface, binding of protease inhibitors like
PAI-l to urokinase causes the complex to be internalized from the cell surface and leads to
degradation of uP NP AI -1 thus inhibiting uP A activity (Cubellis, et al.). This process allows
uP AR to be recycled to the cell surface and thus affects its distribution on the plasma membrane
(Mondino, et al.).

By binding to vitronectin, uP AR has also been found to playa role in cellular adhesion,
migration, and signaling. The roles of uP A and uP AR have been exhibited by the development
and use of uP A and uP AR deficient mice; one such study has shown that uP A deficient mice are
unable to support growth and progression of certain tumors (Mondino, et al.). The urokinase
receptor contains a binding site for vitronectin that is distinct from the one for urokinase. The
strength of the uP AR and vitronectin interaction is increased with the binding of uP AR to uP A in
any of its forms; this shows that the uPAR and vitronectin binding is not dependent on
proteolytic activity (Waltz, et al.). The role ofuPAR in adhesion has been shown to be
dependent upon functional and physical associations with another class of cell surface receptors,
the integrins. Integrins promote cell adhesion, migration, and signalling by their connections to
the cytoskeleton, which uP AR is presumed to utilize. Furthermore, as vitronectin is the major
high affinity PAl -1 binding protein, uP AR binding to it allows for regulation of the proteolytic
process that leads to cell migration and thus links this process to cell adhesion. In order for cell
migration to occur, it must be coordinated with cell adhesion to the underlying cellular or
extracellular matrix. It is affected by adhesion strength and reversibility, which may occur by
certain proeolytic processes that include the urokinase plasminogen system (Chapman and Wei).
As discussed above, the major high affinity binding site ofPAI-1 on vitronectin is in the 5MB
domain. Similarly, research has shown that uP AR binding sequence ofvitronectin is also located
within the central region of the 5MB domain. Another possible binding region on vitronectin is
in the heparin binding domain, and it is being investigated (Deng, et al.). Data has also shown
that integrins bind to vitronectin within the 5MB region.

As seen, the blood glycoprotein vitronectin plays a key role in many processes through the
human body ranging from wound healing to tissue remodelling and tumor progression. Studies
have also shown that vitronectin has an effect on certain infectious organisms that can enter the
human body. One such organism is the opportunistic fungal pathogen Candida albicans. It
causes infections in immunocompromised hosts, such as those undergoing chemotherapy for
tumor reduction in cancer patients and the prolonged use of immunosuppressive agents in organ
transplant patients (Imbert et al.). It has also been found with increased frequency in patients
with human immunodeficiency virus (HIV)-associated acquired immune deficiency syndrome
(AIDS). C. albicans is a dimorphic fungus that shows morphologic switching, being able to
grow in both budding yeast and filamentous hyphal form. The ability to germinate and form
hyphae is thought to be essential for virulence of the organism. It disseminates within the
vasculature of the host and penetrates tissues by adhering to the endothelial basement membrane
and/or subendothelial extracellular matrix components. One such host ECM component that
interacts with C. albicans is vitronectin. Several experiments have shown that microbial
invasion and attachment is mediated by interacting with vitronectin; in the case of C. albicans,
binding of vitronectin mediates fungus adherence to a macrophage cell line. Evidence has
shown that the fungal cells may bind to vitronectin through certain integrin receptors (Santoni, et
al.). One thus sees that, with its function as an adhesive molecule and its role in the immune
system, vitronectin affects the invasion and infection of the pathogen C. albicans. This is also
supported by recent studies which have shown that mice deficient in the vitronectin gene live
longer with C. albicans infection than wild type mice with the infection. This has lead to the
current interest in performing vitronectin binding assays with C. albicans cells.

Because of the many roles and functions that are carried out by vitronectin and their vast
implications in the human body and on the medical field, it has been highly studied in relatively
recent years. Details of the structural and mechanistic aspects of this protein will give insight
into such areas as wound healing, tumor metastasis, and fungal infection. In my research, studies
have been performed to determine the effects of PAI-l on vitronectin with regard to the binding
ofvitronectin to the urokinase receptor. These studies were conducted in vitro and involved such
factors as the presence of extracellular matrix extractions and the usage of the multimeric
vitronectin conformation. Furthermore, experiments were conducted to develop a method to
qualitatively measure the binding of C. albicans fungal cells to vitronectin with the presence of
such factors as PAI-l and extracellular matrix components.

Materials and Methods
These studies, which focused on developing a better understand of the binding of vitronectin to
mammalian cells through the urokinase receptor as well as the binding of Candida Albicans cells
to virtonectin, were conducted using similar methods.

In order to test the effects of P AI -Ion the binding of vitronectin to the urokinase receptor, in
vitro experiments were performed using the methods of enzyme linked immuno-sorbent assays
(ELISAs). For these experiments, vitronectin was purified from plasma in our laboratory and
multimeric vitronectin was made by incubating it with 6 molar urea. Soluble uP AR was
purchased from CalBiochem, and uP A was purchased from R&D Systems. Wild type and
stable (14-1B) PAI-l were purchased from Molecular Innovations. The rabbit anti-uPAR
primary antibody was also purchased from Molecular Innovations. The general protocol for
ELISAs are as follows. A 96-well ELISA plate was coated with vitronectin or isolated
extracellular matrix overnight. The next day, 200 ul of3% BSA in Ix PBS was added to each
well for 1 hour to block the wells. For wells coated with extracellular matrix, vitronectin or a
vitronectin and PAI-l mixture was added to the wells after blocking and left for 1 hour. Both
stable and wild type P AI-I were used in these experiments. After rinsing, soluble uPAR was
added to the wells along with isolated uPA (urokinase plasminogen activator) and incubated for
1 hour. The uPNuPAR complex was formed by incubating 30 nM of each in 0.1% BSA in Ix
PBS for 1 hour. Then a primary antibody was added for 1 hour. Determination of the most
suitable anitbody for the experiments was conducted by performing an ELISA by binding
various primary antibodies to serially diluted uPAR bound wells. Following incubation with the
primary antibody, 100 ul of Peroxidase-labelled Rabbit IgG was added to each well and

incubated for 1 hour. At each step in the process, the plate was rinsed 3 times with a Ix PBS
solution. Then 100 ul of a developing solution was added to each well for 1 hour. The
developing solution consisted of 5 mg ABTS, 20 ul 30% Peroxide, and 25 mls 50 mM sodium
citrate at pH 5.5. Finally, the wells turned a light green color and the binding was measured by
reading the absorbance at 405 nm. The experiments were conducted using varying
concentrations of vitronee tin and PAl-I. To analyze the results, non-specific binding of the
proteins was accounted for by subtracting the background binding of the compounds to the
blocking agent. The majority of the experiments were carried out at room temperature, though a
few mixtures were allowed to incubate at 37 C.

An ELISA based assay was also employed to test the binding of Candida albicans yeast cells to
vitronectin. The wild type C. albicans SC5314 strain was used. Yeast cultures were grown for
each experiment by isolating a colony of C. albicans from a YEPD plate stored at 4C and placing
it in 50 ml solution of media. A new plate was streaked each week. Two different media
solutions were used: a galactose and yeast nitrogen base solution shows greater adhesion of
cells, while a YEPD solution of yeast extract, peptone, and glucose shows less adhesion
properties. The cells are allowed to grow overnight at 30 C while shaking. The cells were
counted and their viability determined by using a trypan blue stain and a hemacytometer. For the
ELISA assay, plates were coated with extracellular matrix or vitronectin overnight. The next
day, 200 ul of a 0.2% Carrageenan solution in Ix PBS was added to each well as a blocking
agent and incubated for 1 hour at room temperature. When extracellular matrix was used,
varying concentrations of vitronectin were incubated for 1 hour at room temperature following
blocking. At this point, 100 ul ofa 3x101\7 cells/ml solution of cells was added to each well, and

the plate was incubated at 37 C for 2 hours to ensure binding. After the cells were incubated on
the plate for 2 hours at 37C, 200 ul ofa developing solution of 0.3 mg/ml XXT, 1.3 mM
Menadione, and Ix PBS was added to each well. As done with the uP AR assays, the wells were
rinsed 3 times with Ix PBS at each step in the process. After the developing solution was
incubated on the plate at 37 C for 1 hour, the plate was read by spectrometry at an absorbance of
490 nm. Again, background binding of the cells is accounted for by subtracting the
measurements of binding to the blocking agent.

Results
uPAR binding assays:
Urokinase receptor (uPAR) binding assays, which are used to give qualitative measures, were
performed to develop a better understanding of the binding of the urokinase receptor to
vitronectin, multimeric vitronectin, and vitronectin in the presence and absence of extracellular
matrix (ECM). Studies were also performed to determine the effects of PAI-l on the interactions
between uPAR and vitronectin. All assays were repeated until results were consistent. Figure 1
shows the effect of the binding affinities of the urokinase receptor to vitronectin when in the
presence and absence ofECM and in the multimeric and monomeric forms. One clearly sees
that the multimeric vitronectin form binds to uP AR with very little affinity both in the presence
and absence of ECM. The presence of ECM increases the binding of monomeric vitronectin to
uP AR. The association between uP AR and multimeric vitronectin is so low that assays with it
and PAI-l were not pursued. Figure 2 shows the effects of wild type and stable PAl-Ion the
binding ofuPAR to monomeric vitronectin in the absence ofECM. This assay illustrates that
both types of PAI-l competitively inhibit uPAR from binding to monomeric vitronectin by a
similar degree. Figure 3 shows similar results for the effects of wild type and stable PAl -Ion
the binding of uP AR to monomeric vitronectin in the presence of ECM. From looking at the
general numbers of the assays in figures 2 and 3, one again sees the enhanced interaction of
uPAR with vitronectin in the presence ofECM. Overall, the data shows that the interaction
between uPAR and vitronectin is negatively affected by the addition of PAl-I. The highest
amount of binding ofvitronectin to the urokinase receptor is seen in the presence of ECM, the
use of monomeric VN, and the absence of PAl -1. These results were shown to be consistent at

various concentrations of the substrates. A linear relationship is also seen in all figures between
the substrate concentrations and the amount of binding.

Candida albicans binding assays:
In order to test the binding of C. albicans cells to vitronectin and the effects of certain factors
including PAI -Ion this binding, certain experimental conditions needed to be determined.
Assays were performed to determine the optimal growing conditions for the C. albicans cells, the
optimal blocking agent for the assays, and the optimum growth media for the cells. The binding
of the cells to ECM was also tested. As with the uPAR assays, experiments were repeated to
show consistency in data. Figure 4 shows the effects of two growing methods on the binding of
different concentrations of cells to the ECM. The conditions that were altered included
temperature, time allotment for incubation, and amount of shaking for the growth of the cells.
Cells were grown at 30 C overnight with shaking and at 37 C for 36 hours without shaking.
Cells grown under these two conditions showed similar amounts of growth and hyphal
formation, and as seen in figure 4, they showed similar amounts of binding to ECM. The
conditions chosen for the assays involved cell growth at 30 C overnight with shaking. Figure 5
shows the data from assays that were performed to determine which type of blocking agent
should be used in the ELISA method to block the cells from binding to the vacant plastic regions
of the wells. From these experiments, a .2% carrageenan solution was found to be the solution to
which the least amount of cells bound. This was shown in comparison with Super block, Casein
block, and BSA; blank wells with no addition of a blocking agent were used as a control. Figure
6 shows the effects of different growth media on the adhesion properties of the C. albicans cells
to ECM. As seen in the figure, growth of cells in galactose media caused the fungal cells to

become very adhesive, while the use ofYEPD media caused cells to exhibit too little adhesive
properties. Because of the linear binding relationship cells grown in the galactose media to ECM
at the lower concentrations, this media was chosen for further assays.

Also, as seen in figure 6,

assays showed that the fungal cells do exhibit increased binding to ECM with increased ECM
concentration. Figure 7 shows the binding of the fungal cells to various concentrations of
vitronectin at constant ECM concentrations. Few differences between vitronectin concentrations
were observed, though a linear relationship seems to be present at low vitronectin concentrations
at the 2.5 ug ECM concentration. Thus, assays with vitronectin have been inconclusive, and
addition of PAI-l has not yet been performed.

Figure 1: uPAR Binding Assay showing decreased
binding with use of multimeric VN form and increased
binding with presence of ECM
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Figure 2: uPAR Biding Assay showing competitive
binding of PAI-1 to monomeric VN in absence of ECM
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Figure 3: uPAR Binding Assay showing competitive
binding of PAI-1 to monomeric VN in presence of ECM
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Figure 4: C. albicans assay showing little difference in
binding to 5 ug/ml ECM due to listed growth conditions
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Figure 5: C. albicans assay showing least cell adhesion
to Carrageenan blocker
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Figure 6: C. albicans assay showing adhesive nature of
cells by type of growth media
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Figure 7: C. albicans assay showing few differences in
binding with varying vitronectin concentrations at
constant ECM conentrations
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Discussion
The urokinase receptor binding assays showed that PAl-1 competitively inhibits the binding of
vitronectin to the cell surface receptor uP AR. This is opposite to observations made on the
interactions ofPAI-l and vitronectin with the integrin class of receptors. The effects of the
presence of ECM and the use of the multimeric vitronectin form were also presented; ECM
presence enhanced the binding while the use of the multimeric form lessened it. These findings
can give insight into the mechanisms and functions of the urokinase plasminogen activator
system, which is involved in many important processes in the human body. This system is
comprised of the serine protease urokinase (uPA), uPAR, PAl-I, and the proenzyme
plasminogen which is cleaved by uP A to form the proteolytic enzyme plasmin. This system
interacts with vitronectin to promote cell adhesion, migration, and signaling. Two schemes have
been developed to explain their role in these processes. In one scheme, by binding uP AR to
vitronectin, cell adhesion is promoted; when PAI-l is present and binds to vitronectin, it is
released from uPAR and the cell is free to migrate. In the other scheme when PAI-I
concentration is low, uPA is active and cleaves plasminogen to form plasmin, which cleaves the
ECM and allows the cell to migrate (Preissner, et al.). The results of this study support the idea
that PAl-1 binds to vitronectin and releases it from uP AR.

This plasminogen system has been shown to be involved in many processes that affect normal
human development and health such as wound healing, tissue remodeling, and cancer. While the
mechanistic functions of the urokinase receptor have been widely researched in terms of its role
as a proteinase receptor in the plasminogen system, evidence has also shown that it is involved in
signaling. This is largely due to its association with such proteins as vitronectin, members of the

integrin adhesion receptor superfamily, and a G-protein coupled receptor. These interactions
allow for the transduction of intracellular signaling pathways that involve cytosolic and
transmembrane kinases, cytoskeletal components and components of the cytoskeleton. These
pathways include effects on cytoskeletal reorganization, intracellular calcium mobilization, and
transcription factor activation (Blasi and Carmeliet).

Increasing evidence has shown that the urokinase plasminogen system, and specifically uP AR, is
an important component in the progression of cancer, in tumor invasion, metastasis and
angiogenesesis. Many clinical studies have shown that high levels of components of this system
are found in tumors and lead to poor patient outcomes. Many of the growth factors needed for
neovascularization, such as vascular endothelial growth factor (VEGF) and interleukins, have
been found to upregulate the levels of uP A and uP AR in multiple cell types, such as
macrophages and tumor stromal fibroblasts, which are involved in tumor progression. Other
experimental studies have demonstrated that regulation of the expression of such plasminogen
system components is beneficial to patient prognosis and outcome; this was shown in both
animal and human systems (Mazar, et al.). As angiogenesis is a process that is necessary for
normal development, the urokinase plasminogen system has also been implicated to playa role
in cardiovascular function due to its interactions with integrins, extracellular matrix, and
vitronectin (Preissner, et al.). This evidence supports the idea that inhibitors ofuPAR and uPA
may serve as potential therapeutic agents against angiogenesis and metastasis. In order to be
able to develop such therapeutic agents, the mechanistic processes of this system and its relation
to other factors in the human body must be better understood. The results of this study are a step
in this direction.

Developing a method to test the binding of Candida albicans cells to vitronectin in the presence
of extracellular matrix and PAl -1 is increasingly important due to the growing evidence of
certain integrin like vitronectin receptors on the fungal cells. These studies would allow for the
development of the mechanistic aspects of C. albicans invasion and pathogenesis as vitronectin
has been hypothesized to be involved. This is supported by the evidence showing that the
distribution of vitronectin in circulation and in the ECM overlaps with C. albicans tissue
dissemination. Vitronectin has been found to mediate interactions of the fungal cells with
phagocytic cells and to human endothelial cells. As C. albicans is an opportunistic pathogen that
is capable of causing serious diseases, a better understanding of its mechanistic function may
lead to beneficial outcomes in the development of anti-fungal therapies (Spreghini, et a1.).

As seen, the results of this research are important to understanding human health and diseases
and may lead to the development of therapeutic agents. Further research must be performed,
though, to provide a better understanding of the detailed processes and interactions involved in
the urokinase plasminogen system and the C. albicans infection system. With regard to
urokinase receptor binding, future studies should include the use of high uP AR expression
mammalian cells to demonstrate the binding interactions. With regard to the C. albicans assays,
a more appropriate growth medium should be investigated for adhesive properties and assays
testing the effects of PAl -Ion binding should be performed.
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